Baoshan Cao
Overview
Explore the profile of Baoshan Cao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao Y, Liu Z, Mannavola F, Cao B
J Gastrointest Oncol
. 2025 Jan;
15(6):2496-2506.
PMID: 39816017
Background: Regorafenib, approved in China for the third-line treatment of patients with metastatic colorectal cancer (mCRC), targets multiple tyrosine kinases. We retrospectively evaluated the efficacy and safety of regorafenib, both...
2.
Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M, et al.
Mol Cancer
. 2025 Jan;
24(1):9.
PMID: 39799325
The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in...
3.
Chen Z, Chen Y, Sun Y, Tang L, Zhang L, Hu Y, et al.
Signal Transduct Target Ther
. 2024 Aug;
9(1):222.
PMID: 39183247
The sole use of single modality data often fails to capture the complex heterogeneity among patients, including the variability in resistance to anti-HER2 therapy and outcomes of combined treatment regimens,...
4.
Wang Z, Cheng S, Yao Y, Liu S, Liu Z, Liu N, et al.
Cancer Immunol Immunother
. 2024 Jul;
73(9):182.
PMID: 38967817
Background: The long-term survival benefit of immune checkpoint inhibitors (ICIs) in neoadjuvant and adjuvant settings is unclear for colorectal cancers (CRC) and gastric cancers (GC) with deficiency of mismatch repair...
5.
Li Q, Guo C, Cao B, Zhou F, Wang J, Ren H, et al.
Thorac Cancer
. 2024 Mar;
15(11):906-918.
PMID: 38462754
Background: To explore the safety and effectiveness of personalized exercise intervention during chemotherapy for lung cancer patients who were relatively weak and with compromised cardiopulmonary function. Methods: Thirty-eight lung cancer...
6.
Wang J, Xu J, Yang S, He L, Xu W, Liu Y, et al.
Mol Carcinog
. 2024 Jan;
63(4):742-756.
PMID: 38270247
Nuclear factor erythroid 2-related factor 2 (Nrf2) significantly contributes to drug resistance of cancer cells, and Nrf2 inhibitors have been vigorously pursued. Repurposing of existing drugs, especially anticancer drugs, is...
7.
Tian Z, Liu Y, Zhu D, Cao B, Cui M
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256661
Objective: this study aimed to identify the relationships between gut microbiota, metabolism, and non-small cell lung cancer (NSCLC) treatment outcomes, which are presently unclear. Methods: in this single-center prospective cohort...
8.
Chen L, Wang F, Zhang H, Cao B
Sci Rep
. 2024 Jan;
14(1):1557.
PMID: 38238429
Several observational studies have revealed an association between autoimmune diseases (AIDs) and colorectal cancer (CRC), although their causal association remained controversial. Therefore, our study used a two-sample Mendelian randomization (MR)...
9.
Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, et al.
Thorac Cancer
. 2024 Jan;
15(5):419-426.
PMID: 38219795
Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs);...
10.
Huang H, Zhang H, Cao B
Thorac Cancer
. 2024 Jan;
15(5):427-433.
PMID: 38211967
Introduction: The prognosis of patients with advanced or metastatic sarcoma is very poor, and a new strategy for patients who fail systemic treatment is urgently required. Apatinib is a small...